MannKind (NASDAQ: MNKD) was upgraded by equities research analysts at JMP Securities from a “market perform” rating to a “market outperform” rating in a research note issued to investors on Friday.

A number of other firms have also recently commented on MNKD. Analysts at Zacks reiterated a “neutral” rating on shares of MannKind in a research note to investors on Thursday. They now have a $2.25 price target on the stock.

MannKind opened at 2.19 on Friday. MannKind has a 52-week low of $1.57 and a 52-week high of $3.95. The company’s market cap is $347.8 million.

MannKind last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.01. Analysts expect that MannKind will post $-0.97 EPS for the current fiscal year.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.

http://www.americanbankingnews.com/2012/08/10/mannkind-upgraded-by-jmp-securities-to-market-outperform-mnkd/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+AmericanBankingNews+%28American+Banking+News%29